Randolph Co Inc Cuts Stake in Johnson & Johnson (NYSE:JNJ)

Randolph Co Inc reduced its position in Johnson & Johnson (NYSE:JNJ) by 0.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 150,936 shares of the company’s stock after selling 251 shares during the period. Johnson & Johnson accounts for about 3.1% of Randolph Co Inc’s portfolio, making the stock its 14th biggest position. Randolph Co Inc’s holdings in Johnson & Johnson were worth $23,658,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. DORCHESTER WEALTH MANAGEMENT Co grew its holdings in shares of Johnson & Johnson by 0.6% during the third quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock valued at $11,758,000 after buying an additional 414 shares during the last quarter. OneAscent Financial Services LLC grew its holdings in shares of Johnson & Johnson by 82.8% during the fourth quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock valued at $1,542,000 after buying an additional 4,457 shares during the last quarter. TrueMark Investments LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $1,458,000. RAM Investment Partners LLC grew its holdings in shares of Johnson & Johnson by 4.5% during the fourth quarter. RAM Investment Partners LLC now owns 1,688 shares of the company’s stock valued at $265,000 after buying an additional 73 shares during the last quarter. Finally, RFG Advisory LLC grew its holdings in shares of Johnson & Johnson by 12.6% during the third quarter. RFG Advisory LLC now owns 18,758 shares of the company’s stock valued at $2,921,000 after buying an additional 2,102 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on JNJ. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday. Raymond James boosted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $177.31.

Johnson & Johnson Trading Down 0.0 %

Shares of Johnson & Johnson stock opened at $147.49 on Tuesday. The firm has a 50-day simple moving average of $157.07 and a two-hundred day simple moving average of $155.90. The company has a market cap of $355.42 billion, a P/E ratio of 10.68, a price-to-earnings-growth ratio of 2.48 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. During the same quarter in the prior year, the firm earned $2.35 EPS. The company’s revenue for the quarter was down 9.7% on a year-over-year basis. As a group, equities analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.